IBEX vs RXT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IBEX exhibits exceptional fundamental health with a Piotroski F-Score of 8/9, indicating strong financial stability and operational efficiency. The stock is currently trading at $27.49, which is essentially at its Graham Number ($27.9) and significantly below its growth-based intrinsic value of $88.79. Despite a bearish technical trend and recent insider selling by the CEO, the combination of a low P/E (9.13), high ROE (33.65%), and robust earnings growth (45.6% YoY) presents a compelling value opportunity.
RXT exhibits severe financial distress, anchored by a weak Piotroski F-Score of 2/9 and a negative Price-to-Book ratio (-0.30), which indicates negative shareholder equity. The company faces a liquidity crisis with a current ratio of 0.68 and stagnant revenue growth (-0.40% YoY). While recent earnings have beaten lowered expectations, the long-term trajectory is catastrophic, evidenced by a 94.2% decline over five years. Combined with aggressive insider selling, the deterministic data suggests a high risk of insolvency or further devaluation.
Compare Another Pair
Related Comparisons
IBEX vs RXT: Head-to-Head Comparison
This page compares IBEX Limited (IBEX) and Rackspace Technology, Inc. (RXT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.